Replies to post #377682 on Anavex Life Sciences Corp (AVXL)

[LBSR TO DA MOON]

4.30 p.m LATE BREAKING ORAL COMMUNICATIONS 
 4.30 p.m LB8 - Top Line Data of ANAVEX®2-73 (blarcamesine) Randomized, Double-blind, Multicenter, Placebo-controlled Phase 2b/3 in  
 Patients with Early Alzheimer’s Disease (AD)  
 Stephen Macfarlane 1 
 , Timo Grimmer 2 
 , Terence O’brien 3 
 , Edward Hammond 4 
 , Walter Kaufmann 4 
 , Emmanuel Fadiran 4 
 , Christopher  
 Missling 4 
 1 
 Hammoncare - Melbourne (Australia), 2 
 THU Munich - Munich (Germany), 3 
 Monash University, Alfred Health - Melbourne (Australia), 4 
 Anavex Life  
 Sciences - New York (United States)